Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery - 25 Jan 2017

Chen Gong

Abstract excerpt

The NCCN has recently released its 2017 version 1.0 guideline for colorectal cancer. There are several updates from this new version guideline which are believed to change the current clinical practice. Update one, low-dose aspirin is recommended for patients with colorectal cancer after colectomy for secondary chemoprevention. Update two, biological agents are removed from the neoadjuvant treatment regimen for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab
Share to Biological Products
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Contraindications

Share to Neoadjuvant Therapy

Share to Nivolumab

Share to Panitumumab

Share to Secondary Prevention

Source

Identifiers

PMID: 28105616

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].PMID 28105616Read ↗

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Semantic proximity Read ↗

Advances in the understanding and treatment of colorectal cancer.Semantic proximity Read ↗

[Improvement of prognostic and predictive network of colorectal cancer based upon the 8th edition of AJCC colorectal cancer staging system].Semantic proximity Read ↗

New Guideline on Managing Colorectal Cancer.Semantic proximity Read ↗

[Ⅱ.BRAF-Mutated Colorectal Cancer-Up-to-Date Evidence and Clinical Practice].Semantic proximity Read ↗

Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Semantic proximity Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.Semantic proximity Read ↗

Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries.Semantic proximity Read ↗

[Colorectal cancer].Semantic proximity Read ↗

BRAF Mutated Colorectal Cancer: New Treatment ApproachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.